生物
免疫
内质网
细胞生物学
降级(电信)
癌症研究
免疫系统
免疫学
计算机科学
电信
作者
Jong‐Ho Cha,Wenhao Yang,Weiya Xia,Yongkun Wei,Li-Chuan Chan,Seung‐Oe Lim,Chia-Wei Li,Tae‐Wan Kim,Shih-Shin Chang,Heng‐Huan Lee,Jennifer L. Hsu,Hung-Ling Wang,Chu‐Wei Kuo,Wei‐Chao Chang,Sirwan M. Hadad,Colin A. Purdie,Aaron McCoy,Shirong Cai,Yizheng Tu,Jennifer Keating Litton
出处
期刊:Molecular Cell
[Elsevier BV]
日期:2018-08-01
卷期号:71 (4): 606-620.e7
被引量:815
标识
DOI:10.1016/j.molcel.2018.07.030
摘要
Metformin has been reported to possess antitumor activity and maintain high cytotoxic T lymphocyte (CTL) immune surveillance. However, the functions and detailed mechanisms of metformin's role in cancer immunity are not fully understood. Here, we show that metformin increases CTL activity by reducing the stability and membrane localization of programmed death ligand-1 (PD-L1). Furthermore, we discover that AMP-activated protein kinase (AMPK) activated by metformin directly phosphorylates S195 of PD-L1. S195 phosphorylation induces abnormal PD-L1 glycosylation, resulting in its ER accumulation and ER-associated protein degradation (ERAD). Consistently, tumor tissues from metformin-treated breast cancer patients exhibit reduced PD-L1 levels with AMPK activation. Blocking the inhibitory signal of PD-L1 by metformin enhances CTL activity against cancer cells. Our findings identify a new regulatory mechanism of PD-L1 expression through the ERAD pathway and suggest that the metformin-CTLA4 blockade combination has the potential to increase the efficacy of immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI